Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Treximet will hit the U.S. market in mid-May, GSK says.

You may also be interested in...



Pozen Wins Injunction To Block Par From Launching Generic Migraine Drug Treximet

A federal judge in Texas finds Pozen's patent infringement claims will likely withstand Par's challenges to validity and enforceability; Pozen received $15.4 million in Treximet royalty revenue in 2010.

Pozen Wins Injunction To Block Par From Launching Generic Migraine Drug Treximet

A federal judge in Texas finds Pozen's patent infringement claims will likely withstand Par's challenges to validity and enforceability; Pozen received $15.4 million in Treximet royalty revenue in 2010.

Short-Selling Reform Is On BIO Wish List For Stimulus Bill

Small public biotechs are especially vulnerable to market manipulation, association notes.

Related Content

Topics

UsernamePublicRestriction

Register

PS067587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel